Erasca To Present SEACRAFT-1 Phase 1 Data At EORTC Symposium
25 Sep 2024 //
GLOBENEWSWIRE
Erasca Reports Second Quarter 2024 Business Updates and Financial Results
12 Aug 2024 //
GLOBENEWSWIRE
Erasca Initiates SEACRAFT-2 Phase 3 Trial For Naporafenib InMutant Melanoma
18 Jun 2024 //
GLOBENEWSWIRE
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib
11 Dec 2023 //
GLOBENEWSWIRE
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs
28 Nov 2023 //
GLOBENEWSWIRE
Erasca Announces Publication of Promising Clinical Data Naporafenib
25 Apr 2023 //
GLOBENEWSWIRE